Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. 1971

J Stokes, and R E Weibel, and V M Villarejos, and J A Arguedas, and E B Buynak, and M R Hilleman

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D008457 Measles A highly contagious infectious disease caused by MORBILLIVIRUS, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the MONONUCLEAR PHAGOCYTE SYSTEM. Rubeola
D008458 Measles Vaccine A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed) Vaccine, Measles
D009107 Mumps An acute infectious disease caused by RUBULAVIRUS, spread by direct contact, airborne droplet nuclei, fomites contaminated by infectious saliva, and perhaps urine, and usually seen in children under the age of 15, although adults may also be affected. (From Dorland, 28th ed) Parotitis, Epidemic,Epidemic Parotitides,Epidemic Parotitis,Parotitides, Epidemic
D009108 Mumps Vaccine Vaccines used to prevent infection by MUMPS VIRUS. Best known is the live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine. Inactivated Mumps Vaccine,Inactivated Mumps Virus Vaccine,Live Attenuated Mumps Vaccine,Live Attenuated Mumps Virus Vaccine,Mumps Vaccine, Inactivated,Mumps Vaccine, Live Attenuated,Mumps Virus Vaccine, Inactivated,Mumps Virus Vaccine, Live Attenuated,Vaccine, Inactivated Mumps,Vaccine, Mumps
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness

Related Publications

J Stokes, and R E Weibel, and V M Villarejos, and J A Arguedas, and E B Buynak, and M R Hilleman
August 1990, American journal of diseases of children (1960),
J Stokes, and R E Weibel, and V M Villarejos, and J A Arguedas, and E B Buynak, and M R Hilleman
December 1975, American journal of diseases of children (1960),
J Stokes, and R E Weibel, and V M Villarejos, and J A Arguedas, and E B Buynak, and M R Hilleman
June 1973, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
J Stokes, and R E Weibel, and V M Villarejos, and J A Arguedas, and E B Buynak, and M R Hilleman
November 1982, The Journal of infectious diseases,
J Stokes, and R E Weibel, and V M Villarejos, and J A Arguedas, and E B Buynak, and M R Hilleman
July 1975, The Journal of pediatrics,
J Stokes, and R E Weibel, and V M Villarejos, and J A Arguedas, and E B Buynak, and M R Hilleman
September 1984, American journal of diseases of children (1960),
J Stokes, and R E Weibel, and V M Villarejos, and J A Arguedas, and E B Buynak, and M R Hilleman
January 2006, Acta dermato-venereologica,
J Stokes, and R E Weibel, and V M Villarejos, and J A Arguedas, and E B Buynak, and M R Hilleman
September 1982, The Tokai journal of experimental and clinical medicine,
J Stokes, and R E Weibel, and V M Villarejos, and J A Arguedas, and E B Buynak, and M R Hilleman
October 1988, Lancet (London, England),
J Stokes, and R E Weibel, and V M Villarejos, and J A Arguedas, and E B Buynak, and M R Hilleman
June 1988, Pediatrics,
Copied contents to your clipboard!